Over the past decade, it has become clear that there is an important subset of memory T cells that resides in tissues-tissue-resident memory T (T RM ) cells. There is an emerging understanding that T RM cells have a role in human tissue-specific immune and inflammatory diseases. Furthermore, the nature of the molecular signals that maintain T RM cells in tissues is the subject of much investigation. In addition, whereas it is logical for T RM cells to be located in barrier tissues at interfaces with the environment, these cells have also been found in brain, kidney, joint and other non-barrier tissues in humans and mice. Given the biology and behavior of these cells, it is likely that they have a role in chronic relapsing and remitting diseases of both barrier and non-barrier tissues. In this Review we discuss recent insights into the biology of T RM cells with a particular focus on their roles in disease, both proven and putative. 
F o c u s o n I n F l a m m at o r y D I s e a s e
Memory T cells provide rapid and highly effective protective immunity against previously encountered pathogens and can recognize a wide variety of antigens, including those from malignant tumors and environmental substances. It was previously thought that memory T cells consisted of two major subsets: central memory T (T CM ) cells and effector memory T (T EM ) cells 1 . T CM cells express the chemokine receptor CCR7 and the vascular addressin L selectin (CD62L), which enables them to access and enter lymph nodes from blood. T EM cells express low levels of CCR7 and CD62L but have receptors that allow them to access peripheral tissues (for example, the E-selectin ligand Cutaneous Lymphocyte Antigen (CLA), which grants them access to the skin, and α 4 β 7 , an integrin that allows them access to the gut 2, 3 ) .
Over the past decade, it has become clear that there is another important subset of memory T cells: tissue-resident memory T cells, or T RM cells. Under physiological conditions, T RM cells reside in epithelial barrier tissues at the interface between the host and the environment, such as the gastrointestinal (GI) tract, respiratory tract, reproductive tract and skin. T RM cells can respond rapidly to pathogen challenge at these sites independently of recruitment of T cells from the blood 4, 5 . They thus mediate the rapid protective immunity that is the hallmark of adaptive immune memory 4 . T RM cells in a barrier tissue are enriched for T cells specific for pathogens and other antigens that have been encountered previously through that barrier epithelium. Thus, the T cell receptor (TCR) repertoire of skin T RM cells is largely different from that of lung T RM cells, and both are different from that of gut T RM cells 5 . However, T RM cells are not simply memory T cells in an unexpected location; rather, they have a transcriptional program that distinguishes them from peripheral blood T EM cells and T CM cells 6 .
The cell-signaling interactions that maintain T RM cells in their resident tissues are the subject of much investigation. The role of T RM cells in human tissue-specific immune and inflammatory diseases is just beginning to be appreciated 5 . In addition, although it is logical for T RM cells to be stationed at interfaces with the environment, they have also been found in brain, kidney, joint and other non-barrier tissues. T RM cells that appear in non-barrier tissues have similar transcriptional programs 7 , and their location, biology and behavior make it likely that they have a role in chronic relapsing and remitting diseases of non-barrier tissues. Here we discuss how T RM cells are generated after an immune response and review both common and distinctive features of T RM cells in various barrier tissues, including skin, lung and GI tract. We also discuss how T RM cells may be formed in sterile non-barrier tissues such as brain and kidney and speculate as to the role of T RM cells in immune and inflammatory diseases involving tissues. Finally, we review the role of T RM cells in cancer and the goal of generating T RM cells through vaccination for both infectious diseases and cancer. The field is developing at a rapid rate, and new observations are being made on an ongoing basis.
Generation of T RM cells during an immune response
Naive T cells circulate between blood and lymph nodes, where they remain for 12-24 h before returning to the blood and then sampling another lymph node microenvironment 8 . Naive T cells are abundant but highly diverse with regard to TCR repertoire, and thus to pathogens r e v i e w to which they may be targeted, such that naive T cells specific for any given antigen are rare 9 . Dendritic cells are the first to encounter infectious challenge in peripheral tissues, and they ferry pathogen fragments to draining lymph nodes, where they present processed peptides (antigens) to naive T cells. Those T cells that recognize the antigen become activated and clonally expand, such that one naive T cell gives rise to tens of thousands of progeny 9, 10 . Although all these T cells derived from a single naive T cell have the same TCR, the expanded T cell population becomes heterogeneous with regard to the homing molecules that are expressed 11 . Some gain the ability to access peripheral tissues, and others retain the capacity to enter lymph nodes from blood (T CM cells). Effector T cells also acquire new functions that are specific to the pathogen encountered; for example, type 1 helper T cells secrete interferon-γ (IFN-γ, a cytokine that induces a broad range of antiviral factors) in response to viral pathogens, and T H 17 cells produce interleukin-17 (IL-17), a potent inducer of neutrophil activation and recruitment, in response to bacterial and fungal pathogens 12 .
The anatomic location of the draining lymph node has an important role in determining the expression of tissue-homing molecules on formerly naive T cells first activated in that microenvironment 11, 13 ( Fig. 1a) . Naive T cells that are activated in skin-draining lymph nodes are induced to express CLA, a glycosylated variant of P-selectin glycoprotein ligand 12,14-16 and a ligand for E-selectin, as well as a subset of chemokine receptors that facilitate skin homing (for example, CCR4, CCR8 and CCR10) [17] [18] [19] . Alternatively, activation of naive T cells in gut-draining lymph nodes induces expression of α 4 β 7 integrin 20, 21 , the receptor of mucosal addressin cell-adhesion molecule (MAdCAM) expressed on post-capillary venules in intestinal lamina propria 22 , as well as the expression of distinct chemokine receptors, including CCR9 (ref. 23) , which binds to CCL25 produced by intestinal epithelium.
The clonally expanding T cell population includes cells that differentiate into tissue-homing effector cells, but also cells that retain CD62L and CCR7 and resemble T CM cells. These latter cells leave the draining lymph node and travel to other lymph nodes, where a subset can differentiate to express different tissue-homing molecules 11 . After effector T cells exit a skin-draining lymph node and enter the blood, those with skin-homing markers are preferentially trapped by inflamed vessels in skin and are extravasated into dermis 24 . These T cells migrate along chemotactic gradients to the pathogen-infected tissue, where they become activated by antigen and produce cytokines and other effector molecules (for example, granzymes) that facilitate pathogen elimination [25] [26] [27] . It is now clear that some of these migrant T cells remain in place as T RM cells long after the pathogen is eliminated. This sequence of events can play out again and again, in multiple barrier tissues, over the lifetime of an organism, and the result is the accumulation of diverse and largely (but not completely) non-overlapping populations of T RM cells in each barrier tissue 4, 5 . Thus, lung contains influenza-specific T RM cells [28] [29] [30] , gut contains rotavirus-specific T RM cells 31 , skin is enriched in Candida-specific T RM cells 32, 33 and reproductive mucosa contains herpes simplex virus (HSV)-specific T RM cells [34] [35] [36] [37] (Fig. 1b) . Human peripheral blood T cells enriched in populations of skin (CLA), gut (α4β7) or lung (CLA and/or α4β7) tropic memory T cells are specific to previously encountered pathogens of those tissues 32 . It was recently shown that the same naive T cells that give rise to these T RM cells also give rise to T CM cells in parallel; thus the T RM cell population in tissue is 'duplicated in antigen specificity' by a population of T CM cells with an identical T cell repertoire 38 .
The process of T RM cell formation involves some additional nuances not mentioned above. For example, when mouse skin is infected with vaccinia virus by scarification, effector T cells accumulate not only at the vaccinated site but throughout the skin 4 , and this was recently shown to be true for skin immunization with proteins and haptens 38 . npg r e v i e w Non-inflamed skin contains post-capillary venules that express low levels of E-selectin, chemokines and intercellular adhesion molecule 1, all of the requisite molecules that allow skin-homing T cells 24 to be extravasated and home to uninfected skin sites. In the same fashion, endothelial molecules specific for gut-homing T cells are expressed on resting lamina propria endothelium 22 , allowing gut-homing T cells to home to normal, non-inflamed gut. Additionally, multiple sequential encounters with a pathogen at distinct sites on skin lead to a further accumulation of pathogen-specific T RM cells throughout the entire skin surface; thus there is a greater number of T RM cells specific for pathogens encountered more frequently 4, 38 . Furthermore, whereas each naive T cell (and its progeny) has a unique TCR, the expanded clone is otherwise heterogeneous. T CM cells have limited effector function or protective capacity 4 , but they have the potential to replenish the T RM cell compartment upon activation 38 . The relationship between T RM cells and T CM cells is unclear, but both express low levels of KLRG-1 (ref. 6 ), a molecule strongly expressed by effector and T EM cells. These data, in addition to a recent report demonstrating skin T RM and lymph node T CM cell clones sharing the same variable sequence (CDR3) of the TCR 38 , indicate that many, if not all, T RM cells and T CM cells have a common precursor. With regard to the balance of T RM cells and T CM cells, a recent report suggests that the mTOR pathway may regulate this balance, as mTOR inhibitors such as rapamycin favor T CM cell generation in mouse models 39 . Another recent study suggests that high expression of the transcription factor T-box specific protein 21, or T-bet, favors T EM cell differentiation over T RM cell differentiation, with lower expression of this protein found in T RM cells 40 .
Although T RM cells are most likely to have evolved to protect humans against infection from dangerous environmental pathogens, it appears that normal flora of tissue microbiomes, as well as innocuous environmental proteins, can induce the production of T RM cells as well. A recent study in mice and humans found that allergic contact dermatitis was mediated by T RM cells that had been generated in response to topically applied allergens 38 . T RM cells were described as early as 2001 (ref. 41) , and the same group demonstrated that T RM cells in gut do not recirculate between parabiotic mice, in contrast to T cells in lymph node and spleen 42 .
Common features of T RM cells in barrier tissues
Homing of T RM cells. T RM cells are characterized by their inability to recirculate from tissue to lymph node to blood 4, [43] [44] [45] [46] [47] , although the factors responsible for this are an area of active research. The glycoprotein CD69 is a marker of T RM cells and is expressed on T RM cells in skin, lung, GI tract and everywhere else T RM cells have been identified [4] [5] [6] 28, [48] [49] [50] . CD69 was originally thought to be a marker of recent T cell activation in lymph node 51 ; however, most T RM cells in tissues have not recently been activated by antigen. CD69 seems to be involved in peripheral tissue retention of T RM cells, which seems to involve downregulation of the G protein-coupled receptor for sphingosine 1 phosphate (S1P1) 52 . There is a gradient of levels of sphingosine 1 phosphate (S1P) in the body in humans and mice, with the lowest levels in peripheral tissue, intermediate levels in lymph node and the highest levels in blood 50, 53, 54 . These S1P gradients normally function to guide T cells out of tissues and into lymph nodes and out of lymph nodes into blood. Expression of CD69 by T RM cells interferes with the cell-surface expression and function of S1P1, thereby blocking the capacity of these T cells to sense S1P gradients and supporting their stationary nature 50 . The transcription factor Kruppel-like factor 2, which normally enhances S1P1 expression, is downregulated in T RM cells, which indirectly enables CD69 expression 53 . The mechanism by which CD69 and S1P1 compete with each other for cell-surface expression is not completely understood 54 .
The chemokine receptor CCR7 is another G protein-coupled receptor that senses molecular gradients of its ligands CCL19 and CCL21 and directs T cells and dendritic cells from peripheral tissues to lymph node via afferent lymphatics 55 . T cells expressing CCR7 are able to migrate in response to gradients of its chemokine ligands, which are normally not abundant in tissue but are at their highest levels in lymph node and afferent lymphatics. It was recently shown in a mouse model that CD4 + T cells in skin require CCR7 to migrate to afferent lymphatics and that blocking CCR7 expression prevents T cells from leaving skin 56 . In human skin, expression of CCR7 was seen on a population of T cells that migrated out of skin (so-called migratory memory T (T MM ) cells), whereas CCR7 − T cells remained in skin as T RM cells 57 . The respective contributions of S1P1-CD69 and CCR7 expression on T cells to the migration of these cells out of tissues have not been determined.
The integrin CD103 (also known as α E , and which pairs with the β 7 integrin chain) is another marker of T RM cells; however, its expression is more predominant on CD8 + T RM cells than on CD4 + T RM cells. It is a known ligand of E-cadherin, a homotypic adhesion molecule expressed by epithelial cells in barrier tissues 58 . In mouse models, CD8 + T cells specific for HSV-1 do not express CD103 before they enter the skin, but they upregulate CD103 expression upon entering epidermis in response to transforming growth factor-β (TGF-β) 6 . CD103 is also expressed by T RM cells in the lung and GI tract, and even in T RM cells in the brain after CNS viral infection 7, 40, 48, 59 . It is tempting to assume that α E β 7 on these cells binds to epithelial cells via interactions with E-cadherin. However, binding to E-cadherin is not required for tissue residence, as CD103 + CD4 + and CD8 + T RM cells can be found in the dermis, and CD103 + dendritic cells are plentiful in the dermis without ever entering the epidermis 60 . Although E-cadherin is expressed during brain development, it is absent in adult CNS tissue 61 , despite abundant CD103 on brain CD8 + T RM cells in mice. Thus, although its role is incompletely understood, it does appear that CD103 expression is a marker of differentiation of T RM cells 6 rather than a functional requirement for tissue residence. It is notable that CD103 + T RM cells have less proliferative potential and more significant effector cytokine-production capacity than do CD103 − T cells in several human and mouse models 7, 40, 41, 48, 59, 62, 63 . Human skin T cells also are not strictly required to express CD103 in order to be T RM cells 57 . A recent study of a mouse model suggests that CD8 + CD103 − T RM cells may have a unique role in gut, as they are generated in inflammatory microenvironments in the lamina propria and have a distinctive role in controlling infection compared to their CD8 + CD103 + counterparts 64 .
Less is known about CD4 + T RM cells than about CD8 + T RM cells, in part because these cells are less efficiently generated after viral infection in mouse models, in which T RM cells have been most completely characterized. Studies of HSV infection of the female mouse reproductive tract suggest that local chemokine gradients from tissue mononuclear cells maintain CD4 + T RM cells in place 37 . In skin, evidence suggests that CD4 + T RM cells do not preferentially localize to the epidermis and express lower levels of CD103 than do CD8 + T cells 4, 63 . HSV-specific CD4 + T cells in mouse skin may be more mobile than CD8 + T RM cells, and they may also be limited to the dermis 65 . CD4 + T cells in skin may express CCR7 and/or CD69 (refs. 5,56) . In a recent study, highly immunocompromised NOD SCID IL-2Rγ-deficient (NSG) mice bearing human skin xenografts were treated with alemtuzumab (an antibody that binds human npg r e v i e w CD52, a molecule present on all T cells). This humanized antibody has been shown to deplete human T cells in blood but not in tissue 57, 66 . Two populations of CD4 + T cells were depleted by alemtuzumab from the skin xenografts of these mice: those that expressed both CCR7 and CD62L (markers of T CM cells), and those that expressed CCR7 but not CD62L (T MM cells). These data demonstrate that these two populations normally migrate out of skin into blood, and thus although they transiently reside in skin, they are not authentic T RM cells. The two populations of CD4 + T cells that remained in the skin after alemtuzumab treatment both expressed CD69 and lacked CCR7 (and were thus unresponsive to S1P and CCL19/21 gradients) and included both CD103 + and CD103 − populations. Thus, four distinct populations of CD4 + T cells could be identified in human skin, two of which were short-term residents and could exit skin and enter blood, and two of which were true T RM cells 57 .
Maintaining T RM cells in tissues. The molecular factors that maintain T RM cells in their resident tissue are not completely understood, but IL-15, TGF-β, tumor necrosis factor-α (TNF-α) and IL-33 have all been implicated 6, 53 . TGF-β, TNF-α and IL-33 have all been shown to have a role in the induction of CD103 expression and acquisition of a T RM cell phenotype. Factors that induce upregulation of CD69 expression include TNF-α and type I interferons 50, 67 . The aryl hydrocarbon receptor is important for the maintenance of γδ T cells in mouse skin 68 , and a recent report suggests that it is important for the generation of αβ-TCR + CD8 + T RM cells 69 . A recently described additional common activity of CD8 + T RM cells is highlighted by several recent papers. One of the first cytokines made by virally induced CD8 + T RM cells upon antigen reactivation is IFN-γ. In both skin and reproductive mucosa, the IFN-γ released by activated T RM cells creates a generalized antiviral microenvironment in tissue by upregulating a series of antiviral and antimicrobial genes in surrounding keratinocytes, enhancing the expression of vascular adhesion molecule in endothelium and activating other resident cells, including natural killer (NK) cells and dendritic cells 70, 71 . In this fashion, activated T RM cells can amplify and activate the innate immune system, creating an environment inhospitable to even completely unrelated viruses and other pathogens.
Properties of T RM cells in distinct barrier tissues
Skin T RM cells. In 2006, it was reported that normal resting human skin contains twice as many T cells as blood does 5, 72, 73 , and it is now appreciated that most but not all of these cells are T RM cells 57 (Table 1) . Thus, memory T cells generated in response to previous pathogen exposure in the cutaneous environment are present in abundance in the skin, allowing for immediate response to pathogenic invasion 5 . These cells have a diverse TCR repertoire and can be activated by pathogens at a much lower threshold than circulating T cells via TCRs 72 . Moreover, they are heterogeneous: they include CD4 + and CD8 + T cells that produce IL-17, IFN-γ, TNF-α, IL-9, IL-13 and other cytokines, alone or in combination 5, 32, [72] [73] [74] [75] [76] .
Mouse models have been instrumental in furthering our understanding of skin T RM cells. Early studies showed that in mice transfused with HSV peptide-specific transgenic T cells and then infected with HSV, the transgenic CD8 + T cells could be transferred from one mouse to another by a previously infected skin graft, and these transferred HSV-specific T RM cells maintained their ability to clear virus upon challenge 63 . In another study it was shown that vaccinia virus (VACV) administration by skin scarification was far superior to other routes of immunization in generating skin-resident CD8 + T RM cells 77 . The same investigators showed that skin T RM cells, in the absence of circulating T cells and antibody, can clear virus on re-challenge to skin. Furthermore, infection by skin scarification leads to the generation of lung T RM cells that, in the complete absence of circulating antibodies and circulating T cells, can partially protect immunized mice from a lethal pulmonary challenge with VACV 77 . Thus, skin immunization can lead to widespread T RM cells throughout the skin as well as in distant barrier tissues. This occurs not only at the site of infection but also at distant sites, and the number of accumulated CD8 + T RM cells throughout the skin increases after multiple infections at distinct sites 4 . However, CD8 + T RM cells do not recirculate, and mice that contain T CM cells but lack T RM cells cannot effectively clear VACV from skin, in contrast to mice that have immune skin T RM cells 4 . Another study showed that after HSV challenge in mice, HSV-specific CD8 + T RM cells migrate to the epidermis and acquire a sessile phenotype, whereas HSV-specific CD4 + T RM cells localize to the dermis and show greater mobility 65 .
Interestingly, the transcriptomes of T RM cells from skin, lung and gut have common core features in mice 6 . A study showed that localization of CD8 + T RM cells in the epidermis and CD103 expression on T RM cells were induced in the epidermis by TGF-β, and these CD8 + T RM cells homed to epidermis via a chemokine-mediated process 6 . Mouse CD8 + T RM cells were also shown to occupy epidermal niches formerly filled by a population of T cells that seed the epidermis before birth-γδ dendritic epidermal T cells (DETCs)-and when viewed by intravital microscopy these cells were found to move laterally between keratinocytes, unlike sessile γδ DETCs. These CD8 + T RM cells interacted transiently with Langerhans cells, suggesting that they were scanning the environment for antigen 69 . In humans, there are two isoforms of the dimeric CD8 molecule on T cells, composed of αβ and αα chains, respectively. After cutaneous HSV infection, CD8-αα + T RM cells localize at the dermal epidermal junction. These cells, but not CD8-αβ + T cells, protect against the reactivation of HSV and lesion formation 78 .
Somewhat less is known about CD4 + skin T RM cells in mice than about CD8 + skin T RM cells. It has been shown, however, that CD4 + regulatory T (T reg ) cells are a major population of T cells emigrating from skin to lymph node after an immune response to contact hypersensitivity, as well as in the absence of stimulus 79 . Another group characterized CD4 + T cells in mouse skin and demonstrated at least two populations, including one that did not leave skin (lacking CCR7 expression) and another that left skin by a CCR7-dependent mechanism, expressed low levels of CD62L and high levels of E-selectin 56 . This is consistent with a very recently published study of T cells in human skin 57 . T RM cells in the GI tract. T RM cells in gut are defined here as T cells that reside in the intestinal epithelium or in lamina propria 80 . It has been shown that a subset of CD103 + dendritic cells in gut-draining lymph node can skew naive T cells toward differentiation into α 4 β 7 + gut-homing memory T cells, primarily under the influence of retinoic acid secreted by these dendritic cells 81 . Gut-infiltrating T cells have been most exhaustively studied in mice during disease states, such as experimentally induced colitis, in which mice lacking CD103 have attenuated inflammation, suggesting a role for T RM cells in inflammation. Until recently 48, 70 , less attention had been paid to T RM cells that emerged after pathogen infection. Several pathogens, including lymphocytic choriomeningitis virus (LCMV), Listeria and others, have been shown to induce the generation of long-lived intraepithelial T cells with potent effector activities in mice 42 . Although many of these pathogens were delivered intravenously in past experiments, in a recent study mice were infected orally with Listeria, and the authors acquired information on gut T RM cells 48 . The study showed that longlived gut T RM cells expressed KLRG-1 at low levels (similar to skin T RM cells), whereas cells with high expression of KLRG-1 (as in T EM cells) that entered gut underwent apoptosis. The oral immunization induced abundant long-lived gut T RM cells, unlike nasal immunization, which induced gut entry by T cells with high KLRG-1 expression that did not persist long term. Gut CD8 + T RM cells express CD69 and CD103, as do mouse skin T RM cells, and their maintenance in the gut is enhanced by TGF-β (ref. 80 ). When transcriptional profiles of skin T RM cells generated in response to HSV infection were compared to those of gut T RM cells induced by an LCMV infection 6 , of 127 genes up-or downregulated in T RM cells relative to expression in T CM cells, 68 showed a pattern common to skin and gut, and the remainder were unique to gut (or possibly to the difference between LCMV and HSV infection) 6 . Thus, the T RM cells that form in gut epithelium and lamina propria have many features in common with T RM cells in other barrier tissues, although they also express gut-specific homing molecules.
Regarding what is known about gut T RM cells in humans, a recent study that surveyed resident T cell populations in various human tissues demonstrated the presence of T RM cells in both colon and small intestine 82 . We have further analyzed human GI tissue by deep sequencing of TCRB and identified a highly diverse T cell repertoire in normal non-inflamed tissue (R.A. Clark et al., data not shown). Liver T RM cells have been demonstrated after malaria infection 83 , and the T cells that infiltrate the liver during viral hepatitis are likely to become tissue resident as well, causing significant and recurrent tissue injury in the absence of effective therapy 84 .
T RM cells in lung and respiratory tissue. The possibility that T RM cells might exist in lung was first considered after the identification of CD69 + CD8 + T RM cells that remained in lung after influenza infection 28 . The original explanation for the expression of CD69 by these cells was that the cells were in an activated state, perhaps as a result of retained antigen; however, we now know that CD69 expression is a generic characteristic of resting T RM cells 29 . There is good evidence that CD8 + T RM cells can be protective against subsequent infection with influenza. Intranasal but not intraperitoneal infection with influenza in mice results in the presence of lung T RM cells, although both routes of infection efficiently produce influenza-specific splenic T EM cells 30 . Furthermore, in the referenced study, the nasal influenza-immunized mice, but not the intraperitoneally immunized mice, were protected against a lethal intranasal challenge with influenza. This echoes work in skin showing that resident, but not circulating, memory T cells are most effective at limiting viral replication at the site of viral entry 4 . However, in this lung-infection study, the T RM cells had essentially vanished from lung 90 d after a single influenza infection. Whether they could be made more abundant at this late stage via boosting strategies such as additional antigen challenge was not explored.
The anatomic location in lung where T RM cells need to reside in order to be most protective against a flu challenge is also controversial; it is clear that lung T RM cells express CD103, and its epithelial ligand, E-cadherin, is expressed most strongly on large and intermediate bronchial epithelial cells and less strongly on small or alveolar epithelia 85 . However, as discussed above, CD103 + cells can persist at a distance from cells expressing E-cadherin. Regarding the levels of CD4 + T cells versus those of CD8 + T cells, TGF-β promotes the development of lung CD103 + CD8 + T RM cells, but in a fashion not dependent on Smad4 (ref. 86) . CD4 + T cells in lung aid in the development of CD103 + CD8 + T RM cells after influenza virus infection 40 , but the respective roles of CD4 + and CD8 + T cells, and whether (as in skin) these two populations have different migratory capacities, have not been explored.
There is a growing body of evidence that points to the existence of T RM cells in normal human lung. T cells have been observed in bronchoalveolar lavage samples, but these are typically acquired in the setting of diseased lung, and thus it is not known whether the cells noted are authentic T RM cells. After pneumonectomy for isolated tumors, human lung tissue very distal to the tumors is histologically normal in appearance 87 , and T cells isolated from such lung samples include CD4 + and CD8 + cells that produce TNF-α and IFN-γ (ref. 87) , express CD69 and have a diverse TCR repertoire; from these data it was estimated that the number of T RM cells in lung approximates the number of T cells in blood-on the order of 10 billion cells. Moreover, these populations of T cells are enriched in the cells that proliferate in response to inactivated influenza virus 87 . Lung T RM cells express abundant α 1 β 1 , although this is expressed in other tissues and is thus not lung specific 87 . CD8 + CD103 + T cells in human lung are specific for influenza, as opposed to CD8 + CD103 − T cells, which are also found in that tissue 59 . T RM cells in human lung were also found in a large survey study that looked at multiple human tissues 82 .
T RM cells in the genitourinary tract. The mucosa of the female reproductive tract is an important barrier tissue. In mouse vaginal HSV infection, CD4 + T cells must first enter the tissue and provide a recruiting cytokine and chemokine signal to facilitate the entry of CD8 + T cells into infected vaginal mucosa 34 . This is different from the process in skin, in which CD4 help is not required to recruit antigenspecific CD8 + T cells after VACV infection 4 . Protective immunity against HSV can also be generated by direct topical infection of the vaginal mucosa followed by the accumulation of T RM cells 35 , which suggests that the generation of T RM cells should be a goal of vaccination 88 . Independently performed studies comparing HSV-infected skin and mucosa have yielded analogous results 36 . Approaches such as these are likely to be used in attempts to generate a protective vaccine against HSV-2. Very recently, it was shown that a local chemokine gradient maintained HSV-specific CD4 + T RM cells in situ, a previously unrecognized mechanism for the maintenance of T RM cell residence 89 . Furthermore, it was recently shown that intravaginal administration of the human papillomavirus (HPV) vaccine in mice led to the generation of CD8 + T RM cells in vaginal mucosa 90, 91 . This work is very promising, as not only HSV and HPV but also HIV can infect through this route, and the possibility of rapidly killing virally r e v i e w infected cells with T RM cells in situ, however they are generated, is appealing (Box 1) 88 . More recently, work on cervical tissue-normal, dysplastic and malignant-has demonstrated that vaccination against oncogenic papillomavirus leads to the generation of T RM cells in these tissues that are highly protective against reinfection 92 .
The role of T RM cells in human disease
Pathologic T RM cells in barrier tissues. The best-characterized role for T RM cells in disease is in mediating skin diseases (Fig. 2) , with fixed drug eruption being the first and best described 93 . Recently, established psoriasis has been shown to be mediated largely by T RM cells. Transcriptomic analysis of resolved lesional psoriatic skin in humans has revealed the presence of T cells and cytokines thought to be important in pathogenesis, suggesting the persistence of these T RM cells 94, 95 . More recently, analysis of cells extracted from resolved psoriatic lesions showed CD8 + T cells that produce IL-17 and CD4 + T cells that produce IL-22, providing additional support for the role of T RM cells in psoriasis 96 . A recent report showed that allergic contact dermatitis in both human and murine settings is also mediated by T RM cells 38 . In psoriasis, the putative antigen is considered to be an autoantigen, whereas in allergic contact dermatitis it is often an innocuous environmental molecule 97 , and in fixed drug eruption it is typically an orally ingested chemical. Recurrence of treated and resolved psoriasis lesions in the same place suggests that although the activity of diseasecausing T RM cells was suppressed by therapy, their localization was unaffected. Vitiligo, as well as some forms of atopic and eczematous dermatitis, may also be mediated by T RM cells 5 ; here the antigen is a melanocyte-specific antigen. Interestingly, a variant of cutaneous T cell lymphoma was found to be a malignancy of T RM cells 98 , and another variant (leukemic cutaneous T cell lymphoma or Sezary syndrome) is a malignancy of skin-homing T CM cells 66, 98 
(Box 2).
The GI tract is another site where certain diseases exhibit the behavior of T RM cell-mediated diseases (Fig. 2) . The discrete waxing and waning skip lesions-areas of disease separated by areas of normal mucosa-in Crohn's disease suggest a role for T RM cells, whereas ulcerative colitis involves a more contiguous circumferential area of the Figure 2 The role of T RM cells in tissue-specific autoimmune and inflammatory disease. Right, diseases of lung, gut and skin clearly or potentially mediated by pathologically activated T RM cells. Left, diseases of normally sterile non-barrier tissues mediated by infiltrating T cells that have acquired the properties of T RM cells. Disease states in normal font indicate that there is experimental evidence supporting T RM cell causation, whereas disease states in italic font are speculation on the part of the authors. GVHD, graft-versus-host disease.
Box 1 T RM cells and vaccination
The observation that pathogenic virus can be rapidly eliminated by T RM cells in animal models, even in the absence of antibody, has led to a burgeoning interest in the induction of T RM cells as a goal of vaccination 4, 77 . Viruses show tissue tropism, with influenza specific for lung, rotavirus specific for gut and HSV specific for skin and other stratified squamous epithelia. T RM cell-based vaccination would direct pathogen-specific T RM cells to the relevant epithelial tissue 88 . Currently, the titer of neutralizing antibodies generated by a vaccine is considered a proxy for its efficacy. But for viruses invading barrier tissues, the process of infection of a resident cell and subsequent hijacking of the cell's program to make more virus is largely insensitive to extracellular antibody. In contrast, such infected cells express viral peptides on cell-surface class I molecules, making them ready targets for CD8 + T RM cells. Vaccination at epithelial surfaces, rather than intramuscularly, is thus a more effective way to generate robust T RM cells 30, 48, 77, 91 . Promising approaches in lung for influenza and in other mucosal tissues have been reported recently 39, 40 .
As proof of principle, in animal models, vaccinia virus (VACV) immunization of skin and lung, influenza infection of lung and Listeria immunization through oral administration have all led to the generation of highly effective tissue-resident T RM cells. A recent HIV vaccine engineered to generate T EM cells showed great promise, and although the investigators focused on blood, they did find memory T cells in mucosal tissue 119 . The wisdom of generating lung T RM cells specific for conserved portions of the influenza virus or anogenital mucosal T RM cells specific for conserved portions of HIV is clear. Virally infected cells could be targeted by T RM cells for elimination shortly after exposure. The challenge with this approach to vaccination is at the level of practicality-how to immunize through an accessible tissue (such as skin) and generate T RM cells in other distant barrier tissues that are specific to the infectious virus. One of several promising approaches involves using VACV vectors delivered via skin scarification; this has been shown to trigger the generation of protective lung T RM cells in one model 77 . Also, because skin immunization in general generates both skin T RM cells and a TCR-identical population of T CM cells in lymph node 38 , sequential skin and peripheral tissue immunization (to convert the T CM cells into tissue-relevant T RM cells) is a possible approach. Although most work on T RM cells has been done in the setting of viral infection, this approach should be applicable to other tissue-selective pathogens. Mycobacterium tuberculosis, Listeria, Vibrio cholerae and Mycobacterium leprae are all candidate pathogens. What remains to be understood is what collection of factors in regional lymph nodes govern the acquisition of tissue-homing markers on effector T cells and how to ensure that these T cells that enter tissue remain as long-lived T RM cells, poised to respond to pathogens through the appropriate environmental interface 88 . npg r e v i e w large intestine 99 . It is unknown, however, whether immune-mediated diseases of the lung (e.g., asthma) involve T RM cells (Fig. 2) . There are no data that address this possibility, although the presence of T RM cells in normal human lung makes the hypothesis a reasonable one. Certainly, the excessive inflammation in lung in the setting of fatal influenza infection may well involve hyperactive T RM cells. Additionally, the fact that T cell-mediated diseases of the skin are mediated by T RM cells, and the finding that these diseases can often be treated with skin-directed rather than systemic therapy, suggests that the approach of local rather than systemic treatment may apply to other tissues as well.
Pathologic T RM cells in non-barrier tissues. It has been shown experimentally that T RM cell accumulation can also occur in tissues generally considered sterile, such as the brain 7 . T RM cells were identified in the brain after intranasal infection with vesicular stomatitis virus, and CD103 + T RM cells had a potent effector function after in vitro stimulation. The transcriptional profile of these brain CD8 + T RM cells resembled that of T RM cells in skin, gut and lung 6, 7 . Whether such T RM cells can form in human brain after viral infection is unknown, and a putative role for these cells in diseases of the CNS requires additional evidence, although recent reports have linked putative pathogenic brain T RM cells to multiple sclerosis (Fig. 2) and even schizophrenia 100, 101 . Although T cell responses in non-barrier tissues may be necessary episodically to deal with a potentially lethal infection, the unintended consequence of such an event may be the generation of long-lived T RM cells and the attendant predisposition to potential autoreactive and autoimmune diseases. One hypothesis is that the potential program for generating T RM cells exists in all activated T cells, and a subset of those that gain entry into tissue (whether a barrier tissue or a normally sterile tissue) show activation of this T RM cell program (Fig. 2) .
Spondyloarthropathies such as human ankylosing spondylitis involve inflammation of entheseal tissues (sites of attachment of tendon to bone), and one recent study in mice demonstrated that entheseal resident T H 17 T RM cells are essential for disease progression 102 . In human rheumatoid arthritis, the clinical recurrence of disease in individual joints bears the hallmarks of a T RM cell-driven process, and a preliminary report describes the presence of T RM cells in human joint synovium in rheumatoid arthritis 103 . It is thus likely that sterile chronic inflammation of peripheral tissues in human disease is mediated by these cells. For example, T cells from blood and kidney were examined in lupus nephritis, and a relatively limited set of T cell clones appeared to be responsible for progressive disease in individual patients, even over periods separated by months to years 104 . Although that study did not examine CD103 or CD69, it provides indirect proof of pathological renal T RM cells (Fig. 2) . In murine models of insulin-dependent diabetes mellitus and pancreatic islet beta cell rejection, infiltrating CD8 + T cells acquire CD103 and remain in place during the immune response 105 . It is conceivable that in human type 1 diabetes mellitus, T cells that infiltrate pancreas and attack beta cells may take on the phenotype of T RM cells (Fig. 2) , favoring their long-term persistence in situ. In solid organ allograft rejection, infiltrating allogeneic T cells are able to acquire T RM cell properties such as CD103 expression 106 , and urinary CD103 is associated with acute graft rejection 107 . If these human diseases involve pathological T RM cells, immunosuppressive regimens may suppress the activation of these cells but have no effect on their location and persistence, thereby setting the stage for recurrence and persistence of disease (Fig. 2) .
Finally, there is evidence that some tissues of immune privilege, such as the eye, may have mechanisms to inactivate T RM cells induced by inflammation 108 through expression of PD-L1 and promotion of T RM Box 2 Cancer and skin-resident T cells Malignacies of T RM cells. Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of T cell malignancies 120 . Recent reports have supported the idea that one form of this disease, mycosis fungoides (MF), is a malignancy of CD4 + T RM cells from skin 66, 98 . MF forms patches and plaques on the skin with well-demarcated borders and tends to recur in precisely the same locations after remission. It is responsive to skin-directed therapy in its early stages 120 . The malignant T cell does not express CD62L, is CLA + CCR4 + and often expresses CD69 (ref. 66) . In advanced stages, T cells can travel to distant skin sites or to lymph node. It is not known whether this represents the acquisition of markers such as CCR7 (which facilitates exit from the skin) or a malignant dedifferentiation program that reduces skin tropism 121 . The other most common type of CTCL is leukemic CTCL, often called Sezary syndrome 98 . In patients with this disease, skin lesions are typically characterized by confluent erythema, also known as erythroderma, and lesions do not have well-defined borders. Malignant T cells are found in skin as well as blood, and sometimes lymph node. The malignant cells bear not only skin-homing markers (CLA, CCR4) but also T CM cell markers (CD62L, CCR7) and have been shown to recirculate between skin and blood. The humanized antibody alemtuzumab depletes CD52 + cells, including the malignant T cell clone, in blood, via a process largely mediated by neutrophil and NK antibody-dependent cell-mediated cytotoxicity 66 . However, even though alemtuzumab binds to T cells in skin, it does not deplete them, owing to an absence of antibody-dependent cell-mediated cytotoxicity effectors. Interestingly, alemtuzumab has absolutely no efficacy in MF, supporting the idea that MF T cells are T RM cells and do not traffic into blood from skin 66 . The antibody has very high efficacy in leukemic CTCL, a malignancy of recently described skin-homing T CM cells 57, 121 .
T RM cells in solid tumors. We have proposed that T cells that enter any solid tissue acquire the T RM cell phenotype, characterized by a unique transcriptional profile including expression of CD69 and CD103 (particularly on CD8 + T cells) and downregulation of KLF-2 and S1P1. The infiltration of tumors, or peritumoral tissue, by T cells (so-called tumor-infiltrating lymphocytes, or TILs) is associated with a better long-term response 122 . One recent study suggested that such infiltration was predictive of the response to immunotherapy with antibodies to PD-1 (ref. 123 ). CD103 expression on T RM cells in ovarian cancer is predictive of a more favorable prognosis 124 , and analogous results were recently seen in lung cancer 125 . Thinking of T cells entering tumors or peritumoral tissue as having a T RM cell phenotype may be a useful way of conceptualizing these cells. Expression of inhibitory molecules such as PD-L1 on tumor stroma or the production of other immunosuppressive factors will blunt the activity of these tumor-specific T RM cells. However, work with antibodies to PD-1 and PD-L1 suggests that activating these T cells may be a highly effective means of activating immune-mediated tumor destruction 112, 123 . Because tumors that contain TIL T RM cells respond well to PD-1-blocking therapy, it is likely that it is important to generate de novo TILs in TIL-poor tumors. Even if these new TILs become suppressed in the tumor microenvironment, the patients may respond to PD-1-PD-L1 blockade.
npg r e v i e w cell PD-1 expression 109 . Through mechanisms that include PD-1-PD-LI interactions, cancer tissues can acquire similar immune privilege. Binding of T cell PD-1 to its natural ligand PD-L1 induces a state of T cell unresponsiveness. Tumor-infiltrating lymphocytes (TILs) by definition become 'resident' in neoplastic tissue. It is notable that TILs with surface markers of T RM cells were found to be predictive of a more favorable prognosis in ovarian cancer 110 . The role of PD-1-PD-L1 interactions in suppressing the activity of TILs in malignant melanoma, and its reversal by therapeutic antibodies that block this interaction, is now well established 111, 112 .
Conclusions
In barrier tissues at interfaces with the environment, T RM cells are an important part of adaptive immune memory, providing the capacity to rapidly address and clear tissue infections caused by previously encountered pathogens. When T RM cells pathologically accumulate in barrier tissues in response to innocuous antigens, disease can result. The molecular program that facilitates the T RM cell phenotype in barrier tissues can be activated in other tissues as well, where persistent immune-driven inflammation can cause chronic disease. Previously, when T cells were seen in pathologic infiltrates, it was assumed that this represented chronic and dynamic T cell infiltration, regardless of the tissue involved. It is more than a semantic difference to propose that these infiltrates in fact include resident populations of T cells in which a T RM cell molecular program has been activated. If this is the case, therapies that suppress T cell function do not necessarily change T cell localization, and reactivated T RM cells will mediate recurrent disease. Whether in CNS, joint, pancreas, kidney or heart, persistent and activated T RM cells in sterile tissues (where they were not intended to be) may drive human autoimmune and inflammatory diseases. Therapies directed at selectively eliminating these T RM cells, by depletion or through modification of the cells' ability to persistently reside in tissue, represent potential approaches to the treatment of such diseases.
It is worth noting that skin T RM cells have been unknowingly targeted for decades, with relevant treatments far predating appreciation of these cells' existence. Skin-directed therapies, ranging from topical corticosteroids to UV-based phototherapy to low-dose radiation, have all led to the remission of what are now understood as T RM cell-mediated diseases. Would gut mucosal-directed therapy via endoscope or synovial-directed therapy via arthroscope suppress T RM cells in those tissues? The advantage of skin-targeted therapy is that repetitive therapy is straightforward and noninvasive, and the results can be assessed without sophisticated imaging techniques. Other approaches might be directed at features that maintain T RM cells in tissue, namely, CD69 and CD103. Blocking or interfering with the function of these molecules might flush pathogenic T RM cells out of tissues, although of course a balance would have to be struck in the depletion of pathogenic T RM cells and physiologically protective normal T RM cells. Finally, it was noted that T RM cells in immune-privileged sites such as the eye express PD-1, and presumably remain quiescent in this fashion. We speculate that TILs are a form of T RM cell and that the tumor may induce PD-1 expression on these tumor T RM cells to suppress their activity. In tumor immunotherapy, the goal is to interfere with this immune suppression with antibodies that block PD-1-PD-L1 interactions. However, if this suppressive pathway exploited for immune privilege could be exploited in non-cancer diseases where unrestrained T RM cell activity causes tissue inflammation and injury, yet another approach to suppressing disease-causing T RM cells would exist. None of these approaches (save those long employed in skin) is more than hypothetical at present. However, what is clear is that although simply suppressing the activation of T RM cells in psoriasis, inflammatory bowel disease or inflammatory arthritis may lead to transient clinical remission, disease recurrence is nearly inevitable if T RM cells persist (as they are designed to do) in tissue. The next decade of T RM cell biology will be devoted to modifying the cells' behavior and, perhaps, long-term residence and location.
